ABDX - Ticker AI Digest

Abingdon Health Plc 📰 1
8.84 | Today 1.03%
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (ABDX) 1
ABDX 06:01
Abingdon Health Plc
EMI Share Option Scheme
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 1
ABDX 06:01
Abingdon Health Plc
£4.8m contracts awarded
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Abingdon Health PLC has been awarded £4.8 million in contracts to develop and manufacture multiplex quantitative lateral flow assay systems for a USA-based customer. The 27-month project includes full program management, regulatory processes, and analytical/clinical performance services, leveraging Abingdons expertise in lateral flow <mark style="background-color:yellow">test</mark> development, manufacturing, and regulatory services across its UK and US facilities. These contracts validate Abingdons integrated CDMO/CRO services and reinforce its position as a leader in end-to-end lateral flow test development.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 1
ABDX 06:01
Abingdon Health Plc
Half-year Financial Report
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary of Abingdon Health PLC Half-Year Financial Report (H1 FY26)**
**Financial Performance**
**Revenue Growth**Total revenue (including grant-funded income) increased by 45% to £4.5 million (H1 FY25: £3.1 million). Reported revenue grew by 37% to £4.2 million.
**Adjusted EBITDA Loss**Improved to £1.7 million (H1 FY25: £1.9 million) due to continued investment in infrastructure and growth.
**Loss Before Taxation**£2.3 million (H1 FY25: £2.6 million).
**Cash Position**Cash and equivalents rose to £3.7 million at 31 December 2025 (30 June 2025: £1.9 million), boosted by a £3.2 million fundraise in October 2025.
**Operational Highlights**
**US Expansion**Expanded CDMO operations in Madison, Wisconsin, with plans for further investment in manufacturing, performance evaluation, and ISO accreditation.
**Major Contracts**Secured a $2.5 million contract in March 2026 for clinical self-test development and regulatory support, adding to a $2 million US contract announced in November 2025.
**Regulatory Services**Revenue grew 49% to £1.9 million, driven by integrated service offerings.
**Innovation**Launched seaweed-based lateral flow housings in partnership with SymbioTex Ltd, emphasizing sustainability.
**Patents**New European patent granted for AppDx® lateral flow smartphone reader, protecting proprietary AI-driven technology.
**Management Changes**Promoted Candice Vendettuoli to Chief Delivery Officer and Natalie Thrush to Chief of Staff to support growth.
**Outlook and Guidance**
**H2 FY26**Expected to be profitable and cash flow positive, with positive adjusted EBITDA.
**FY26 Revenue Guidance**Maintained at £12.6 million (£12.2 million from contracts, £0.4 million from grants).
**FY27 Outlook**Positive, with major CDMO contracts continuing into FY27, providing a strong revenue foundation.
**OTCQB Listing**Shares to begin trading on the OTCQB Venture Market in the US under ticker "ABDXF" to enhance investor accessibility.
**Strategic Focus**
**End-to-End Services**Strengthened by acquisitions of CS Lifesciences and IVDeology, offering comprehensive CDMO, regulatory, and analytical services.
**Sustainability**Commitment to reducing plastic waste in lateral flow products through innovative biobased solutions.
**US Market**Focus on US expansion to capitalize on the growing lateral flow assay market, projected to reach $25.28 billion by 2035.
**Chairman’s Statement**
Dr Chris Hand highlighted substantial revenue growth, strategic investments, and a clear path to profitability. The company’s integrated service offering and strong pipeline position it well for continued growth, with FY27 expected to build on FY26 momentum.
**Conclusion**
Abingdon Health PLC demonstrated robust H1 FY26 performance, with significant revenue growth, strategic advancements, and a positive outlook for H2 FY26 and beyond. The company is well-positioned to capitalize on the lateral flow market’s growth, supported by its expanded US operations, innovative product offerings, and strong contract pipeline.
Results 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 4
ABDX 06:01
Abingdon Health Plc
EMI Share Option Scheme
ABDX 06:01
Abingdon Health Plc
Trading to commence on the OTCQB in the US
ABDX 06:01
Abingdon Health Plc
£4.8m contracts awarded
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Abingdon Health PLC has been awarded £4.8 million in contracts to develop and manufacture multiplex quantitative lateral flow assay systems for a USA-based customer. The 27-month project includes full program management, regulatory processes, and analytical/clinical performance services, leveraging Abingdons expertise in lateral flow <mark style="background-color:yellow">test</mark> development, manufacturing, and regulatory services across its UK and US facilities. These contracts validate Abingdons integrated CDMO/CRO services and reinforce its position as a leader in end-to-end lateral flow test development.
ABDX 06:01
Abingdon Health Plc
Half-year Financial Report
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary of Abingdon Health PLC Half-Year Financial Report (H1 FY26)**
**Financial Performance**
**Revenue Growth**Total revenue (including grant-funded income) increased by 45% to £4.5 million (H1 FY25: £3.1 million). Reported revenue grew by 37% to £4.2 million.
**Adjusted EBITDA Loss**Improved to £1.7 million (H1 FY25: £1.9 million) due to continued investment in infrastructure and growth.
**Loss Before Taxation**£2.3 million (H1 FY25: £2.6 million).
**Cash Position**Cash and equivalents rose to £3.7 million at 31 December 2025 (30 June 2025: £1.9 million), boosted by a £3.2 million fundraise in October 2025.
**Operational Highlights**
**US Expansion**Expanded CDMO operations in Madison, Wisconsin, with plans for further investment in manufacturing, performance evaluation, and ISO accreditation.
**Major Contracts**Secured a $2.5 million contract in March 2026 for clinical self-test development and regulatory support, adding to a $2 million US contract announced in November 2025.
**Regulatory Services**Revenue grew 49% to £1.9 million, driven by integrated service offerings.
**Innovation**Launched seaweed-based lateral flow housings in partnership with SymbioTex Ltd, emphasizing sustainability.
**Patents**New European patent granted for AppDx® lateral flow smartphone reader, protecting proprietary AI-driven technology.
**Management Changes**Promoted Candice Vendettuoli to Chief Delivery Officer and Natalie Thrush to Chief of Staff to support growth.
**Outlook and Guidance**
**H2 FY26**Expected to be profitable and cash flow positive, with positive adjusted EBITDA.
**FY26 Revenue Guidance**Maintained at £12.6 million (£12.2 million from contracts, £0.4 million from grants).
**FY27 Outlook**Positive, with major CDMO contracts continuing into FY27, providing a strong revenue foundation.
**OTCQB Listing**Shares to begin trading on the OTCQB Venture Market in the US under ticker "ABDXF" to enhance investor accessibility.
**Strategic Focus**
**End-to-End Services**Strengthened by acquisitions of CS Lifesciences and IVDeology, offering comprehensive CDMO, regulatory, and analytical services.
**Sustainability**Commitment to reducing plastic waste in lateral flow products through innovative biobased solutions.
**US Market**Focus on US expansion to capitalize on the growing lateral flow assay market, projected to reach $25.28 billion by 2035.
**Chairman’s Statement**
Dr Chris Hand highlighted substantial revenue growth, strategic investments, and a clear path to profitability. The company’s integrated service offering and strong pipeline position it well for continued growth, with FY27 expected to build on FY26 momentum.
**Conclusion**
Abingdon Health PLC demonstrated robust H1 FY26 performance, with significant revenue growth, strategic advancements, and a positive outlook for H2 FY26 and beyond. The company is well-positioned to capitalize on the lateral flow market’s growth, supported by its expanded US operations, innovative product offerings, and strong contract pipeline.

AI Crunch

Single-Ticker AI Crunch
ABDX signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for Abingdon Health Plc. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full ABDX AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for ABDX on 2026-04-15.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
21781004
Enterprise Value
4187469
Public Float
66.76
Broker Target
19
Shares Out
251077850
Long Interest
-
Short Interest
-
Exchange
LSE
Currency Code
GBX
ISIN
GB00BLF79J41
Market
LSE - AIM
Sector
Medical Equipment and Services
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2026-04-01
Net Debt
-890000.0
Cash
1918000.0
EPS
-0.01
Net Income
-3415000.0
Revenue
8429000.0
Enterprise Value
4187469
Trailing PE
-
Forward PE
53.1915
Price Sales TTM
2.2755
Price Book MRQ
3.1878
EV Revenue
1.8102
EV EBITDA
-0.2499

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
44.9753
Institutions As Of
2025-11-04
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
0
Sale Director Dealing
0
Purchase TR1
6
Sale TR1
1
Broker Coverage Rows
0
Institution Holders Tracked
5
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

1 live catalyst just hit ABDX.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2026-04-15 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
1 Today
Catalyst Pulse
Abingdon Health Plc has fresh news flow feeding the chart narrative.
06:01 Today's Catalyst EMI Share Option Scheme
AI Charts Studio
ABDX Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2026-04-15 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast -25.34%
RSI Gauge
Price Change
AI Forecast